Claims
- 1. A method for inhibiting the growth and or proliferation of ovarian cancer cells comprising bringing IL-19 polypeptide into contact with the ovarian cancer cells in an amount sufficient to inhibit or reduce the proliferation of the ovarian cancer cells.
- 2. A method for treating a female mammal afflicted with ovarian cancer comprising administering to the female an isolated IL-19 polypeptide an amount of a composition of IL-19 polypeptide sufficient to inhibit or reduce the proliferation of the ovarian cancer.
- 3. The method of claim 2, wherein the IL-19 polypeptide is administered in conjunction with radiation.
- 4. The method of claim 2, wherein the IL-19 polypeptide is administered in conjunction with a chemotherapeutic agent.
- 5. The method of claim 4, wherein the chemotherapeutic agent is selected from the group consisting of paclitaxel, cisplatin, carboplatin, topotecan, hexamethylmelamine, ifosfamide, doxorubicin, bleomycin, Taxol, and etoposide.
- 6. A method for treating a female mammal afflicted with ovarian cancer comprising administering to the female an isolated IL-19 polypeptide an amount of a composition of IL-19 polypeptide sufficient to inhibit or reduce the proliferation of the ovarian cancer, and wherein the IL-19 polypeptide is fused with a cytotoxic moiety.
- 7. The method of claim 6, wherein the cytotoxic moiety is a bacterial or plant toxin, cytotoxic radionuclide or cytotoxic drug.
- 8. A method of reducing proliferation of ovarian cancer cells comprising administering to a mammal with a ovarian neoplasm an amount of a composition of IL-19 polypeptide sufficient to reduce proliferation of the neoplastic ovarian cells.
- 9. The method of claim 8, wherein the IL-19 polypeptide is administered in conjunction with radiation.
- 10. The method of claim 8, wherein the IL-19 polypeptide is administered in conjunction with a chemotherapeutic agent.
- 11. The method of claim 9, wherein the chemotherapeutic agent is selected from the group consisting of paclitaxel, cisplatin, carboplatin, topotecan, hexamethylmelamine, ifosfamide, doxorubicin, bleomycin, Taxol, and etoposide.
- 12. The method of claim 8, wherein the IL-19 polypeptide is fused with a cytotoxic moiety.
- 13. The method of claim 12, wherein the cytotoxic moiety is a bacterial or plant toxin, cytotoxic radionuclide or cytotoxic drug.
REFERENCE TO RELATED APPLICATIONS
[0001] The present application is related to U.S. Provisional Application Serial No. 60/372,344 filed Apr. 11, 2002. Under 35 U.S.C. §119(e)(1), this application claims benefit of said Provisional Applications.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60372344 |
Apr 2002 |
US |